Jeroen Van Beek, PhD
About Jeroen Van Beek, PhD
Jeroen Van Beek, PhD, serves as the Chief Commercial Officer at AlloVir, an ElevateBio Company, and has extensive experience in the pharmaceutical industry, particularly in hematology and oncology. He holds a PhD in Chemistry and an MBA, and is recognized for his expertise in commercialization strategy and launching products for rare diseases.
Work at AlloVir
Jeroen Van Beek serves as the Chief Commercial Officer at AlloVir, an ElevateBio Company, since 2019. In this role, he focuses on developing and implementing commercialization strategies for the company's innovative therapies. His leadership is instrumental in driving the company's growth and market presence in the Greater Boston Area.
Current Role at ElevateBio
In addition to his position at AlloVir, Jeroen Van Beek has been a Senior Commercial Advisor at ElevateBio since 2018. His responsibilities include advising on commercial strategies and market access initiatives, leveraging his extensive experience in the biotechnology sector to support the company's mission.
Professional Background
Jeroen Van Beek has held various significant positions throughout his career. He worked as the Marketing Director for Oncology at Pfizer from 1999 to 2007 and served as Vice-President of Global Commercial Operations & Development at Alexion Pharmaceuticals from 2007 to 2017. He also briefly held the role of Chief Commercial Officer and Senior Vice President at Tricida, Inc. in 2018.
Education and Expertise
Jeroen Van Beek has a multi-disciplinary educational background. He earned a Bachelor of Science in Chemistry from the University of Virginia, followed by a Doctor of Philosophy (PhD) in Chemistry from Cornell University. He also holds an MBA from the University of Virginia Darden School of Business. His education supports his expertise in commercialization strategy, market access, and product launch, particularly in the field of rare diseases.
Achievements in Commercialization
Jeroen Van Beek is recognized for his proven track record in launching first-in-class products globally for rare diseases. He has significant experience in building high-performing commercial teams and developing new markets. His ability to translate scientific and clinical results into effective product commercialization strategies has been a key factor in his success in the hematology and oncology sectors.